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Background: The increasing prevalence of diabetes is associated with increased health care use and costs.
Innovations to improve the quality of care, manage the increasing demand for health care and control the growth
of health care costs are needed. The aim of this study is to evaluate the care process and costs of managed,
protocolized and usual care for type 2 diabetes patients from a societal perspective.
Methods: In two distinct regions of the Netherlands, both managed and protocolized diabetes care were
implemented. Managed care was characterized by centralized organization, coordination, responsibility and
centralized annual assessment. Protocolized care had a partly centralized organizational structure. Usual care was
characterized by a decentralized organizational structure. Using a quasi-experimental control group pretest-posttest
design, the care process (guideline adherence) and costs were compared between managed (n = 253), protocolized
(n = 197), and usual care (n = 333). We made a distinction between direct health care costs, direct non-health care
costs and indirect costs. Multivariate regression models were used to estimate differences in costs adjusted for
confounding factors. Because of the skewed distribution of the costs, bootstrapping methods (5000 replications)
with a bias-corrected and accelerated approach were used to estimate 95% confidence intervals (CI) around the
differences in costs.
Results: Compared to usual and protocolized care, in managed care more patients were treated according to
diabetes guidelines. Secondary health care use was higher in patients under usual care compared to managed
and protocolized care. Compared to usual care, direct costs were significantly lower in managed care (€-1.181
(95% CI: -2.597 to -334)) while indirect costs were higher (€758 (95% CI: -353 to 2.701), although not significant.
Direct, indirect and total costs were lower in protocolized care compared to usual care (though not significantly).
Conclusions: Compared to usual care, managed care was significantly associated with better process in terms of
diabetes care, fewer secondary care consultations and lower health care costs. The same trends were seen for
protocolized care, however they were not statistically significant.
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The increasing prevalence of diabetes is associated with
an increase in health care use and costs [1]. Innovation
to improve quality of care, manage the increasing de-
mand for health care and control the growth of health
care costs is needed [1,2]. There is increasing awareness
that tackling the growing societal and economic burden
brought about by diabetes will require nothing less than
a transformation of health care, from a system that reacts
to acute episodes of illness to one that seeks to pro-
actively maintain health [3-5]. Several deficiencies exist in
the current management of diabetes, including a lack of
care coordination, limited follow-up of patients over time,
inadequate training in self-management skills and insuffi-
cient adherence to evidence-based guidelines by care pro-
viders. As a result, discrepancies exist between care as
recommended and care as received by patients [6-8].
In recent years, targeted programs have become an im-
portant means of improving the quality of diabetes care
and overcoming existing deficiencies [7-9]. A wide array
of approaches exists including the Chronic Care Model
[10,11] and managed care [12]. A common characteristic
of chronic care programs is their underlying assumption
that increasing the quality of care will result in improved
health outcomes. Studies evaluating the effects and costs
of diabetes care, including elements of the Chronic Care
Model, have shown inconsistent results [4,9,13-20]. In
general, these studies did not include a control group or
information on costs from a societal perspective.
In two distinct regions of the Netherlands, diabetes
care was implemented at the primary care level with a
different degree of organization in each region. In the
first region, managed diabetes care based on the Chronic
Care Model was implemented, characterized by central-
ized organization, coordination, responsibility and central-
ized annual assessment. In the second region, protocolized
care was implemented at the primary care level, with cen-
tralized organisation and coordination and decentralized
responsibility and annual assessment. We hypothesized
that managed and protocolized care are associated with a
better process of care (adherence to diabetes guidelines)
and lower costs compared to usual care, which is charac-
terized by a decentralized organizational structure.
The aim of this study was to evaluate the process and
costs of managed diabetes care and protocolized diabetes
care as compared to usual diabetes care.
Methods
In this pragmatic controlled trial, the processes and
costs of diabetes care were compared between patients
receiving managed care, patients receiving protocolized
care and patients receiving usual diabetes care. Measure-
ments were performed before and after the implementa-
tion of protocolized care and compared between thethree groups using a quasi-experimental control group
pretest-posttest design.
The care groups were compared and evaluated accord-
ing to the Dutch guidelines for type 2 diabetes [21]. Ac-
cording to these guidelines, patients should visit their
general practitioners’ (GP) practice four times a year for
a diabetes assessment in which weight and fasting blood
glucose are measured. Blood pressure is recommended
to be measured when antihypertensive medication is
used. Foot screening is recommended to be performed
in patients at risk for developing ulceration. Patients’
well-being, lifestyle and medication use should be dis-
cussed. Once a year, the assessment must be expanded
to include measurement of blood pressure, lipids and
HbA1c and screening for complications, among other
things. To perform screening for retinopathy, the patient
is referred to a specialist in ophthalmology.
Usual care
Usual diabetes care has a decentralized organizational
structure and the patient’s own GP is responsible for dia-
betes care. Patients of all GPs should receive diabetes
care according to the Dutch guidelines for type 2 diabetes
[21]. In the usual care group, 17 GP’s throughout the
Netherlands were included and their diabetes patients
were invited to participate in our study. The GPs in the
usual care group are affiliated with the Continuous Mor-
bidity Registration sentinel stations of The Netherlands
Institute for Health and Services Research [22]. This net-
work of general practices represents 0.8% of the Dutch
population and is representative at a national level for age,
sex, geographic distribution and population density. The
possibility exists that GPs in the usual care group partici-
pate in some form of disease management for type 2 dia-
betes patients.
Managed diabetes care
According to the Chronic Care Model, improvement of
care can be achieved by separating acute care from the
planned management of chronic diseases, offering the pa-
tient education about the disease and enabling supporting
self-management. A computerized information system is
used to provide a reminder to comply with evidence-based
guidelines in planning individual patient care and in giving
feedback to caregivers about their performance [3,4].
In 1996, managed care was implemented in the Dia-
betes Care System (DCS) in the West-Friesland region
of the Netherlands, based on the Chronic Care Model.
In contrast with usual care, in which the GP is respon-
sible for the diabetes care, the DCS is responsible for the
execution and quality of diabetes care and organizes dia-
betes care centrally and coordinates the care across all
care providers. Using a centrally organized database, pa-
tients’ clinical information is accessible to the health care
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treated by the DCS receive an annual extended diabetes
assessment at the specialized Diabetes Care Centre in
addition to the diabetes care offered by the patients’ GPs.
During this assessment BMI, blood pressure, HbA1c, lipid
levels, fasting glucose level and kidney function are
measured. Screening for cardiovascular diseases, retinop-
athy and complications of the foot is performed at the
centre. Patients have a central role in their care and self-
management is stimulated by providing education and in-
formation programs. Moreover, individual care plans are
discussed with the patient and patients are encouraged to
make their own choices with respect to treatment options
and lifestyle behaviour. Diabetes nurses visit participating
GPs twice a year to provide feedback on their perform-
ance. Individual patients are evaluated and mean values
of risk factors of the GP’s diabetes population are com-
pared to those of the diabetes populations of other par-
ticipating GPs.
Protocolized diabetes care
In 2007, protocolized care was implemented in 12 general
practices in the Amstelland region of the Netherlands. This
form of care focuses mainly on the adherence to guidelines
for type 2 diabetes. In addition to usual care, a web-based
database for the registration of diabetes-related data is used
and is also applied to monitor mean values of risk factors
and whether or not patients received diabetes care in line
with the Dutch guidelines for type 2 diabetes. Education is
offered to all health care professionals involved to increase
their expertise in the field of type 2 diabetes. In contrast
to managed diabetes care, all assessments are performed
in a patient’s own GP’s office and there is no centrally
organized assessment.
The presence of specific elements by type of diabetes
care are presented in more detail in the online Additional
file 1: Table S1.
Patient selection
Type 2 diabetes patients, between 40 and 75 years of age
and capable of understanding the Dutch language were
eligible for this study. From July 2007 to May 2009, dia-
betes patients that fit these criteria were invited to par-
ticipate in the study.
The study population consisted of three subpopula-
tions. For the managed care group, a random sample of
643 patients received an invitation to participate in this
study and 313 (49%) patients participated. For the proto-
colized care group, a random sample of 802 patients re-
ceived an invitation to participate of which 293 (37%)
patients were included. For the usual care group, a ran-
dom sample of 1098 patients was invited and 485 (44%)
patients participated. Patients with type 1 diabetes, defined
as diabetes with onset before the age of 40 in combinationwith insulin treatment, were excluded (managed care: n =
3; protocolized care: n = 4; usual care: n = 13). After exclu-
sion of patients without a completed cost diary both at
baseline and one year after baseline, 215 patients receiving
managed care, 197 patients receiving protocolized care
and 333 patients under usual care were eligible for the
analyses. Patients who did not complete two cost diaries
were younger (64 vs. 65, p = 0.01) and were less likely to
be married or living together (73 vs. 80, p = 0.02) com-
pared to patients who completed two cost diaries. Other
characteristics of the participants included were similar to
those who had not completed two cost diaries.
All participants provided written informed consent.
Ethical approval for the study was obtained from the
Ethical Review Committee of the VU University Medical
Center Amsterdam.
Measurements
Information on marital status, educational level, work sta-
tus, smoking habits, diabetes duration, type of treatment
(dietary advice or medication) and performance of assess-
ments and screenings was obtained by self-administered
questionnaires.
Costs
All participants were asked to complete a prospective
cost diary over the course of three months at baseline
and over the course of three months one year later. The
cost diary is considered a valid method of obtaining infor-
mation on costs [23]. If we did not receive a completed
cost diary and the patient did not respond to a reminder,
or in the event of an incomplete diary, we attempted to
collect this missing data in a telephone interview.
Information on costs from a societal perspective was
obtained and included direct health care costs, direct
non-health care costs and indirect costs attributable to
type 2 diabetes. The cost diary included questions re-
garding visits to health care providers related to diabetes
care. Patients also reported visits, if any, to the GP, men-
tal health care providers and complementary health pro-
fessionals. Patients were asked to specify visits to other
medical specialists and therapists. Laboratory tests, use
of home care and hospitalization were also reported. Fi-
nally, indirect costs were measured by asking the patient
about loss of productivity (absenteeism from paid and un-
paid work). Dutch unit prices were used to calculate costs
of resource use (online Additional file 1: Table S2) [24].
Statistical analysis
Characteristics of the population are presented as means
(SD), median (interquartile range) or proportions accord-
ing to diabetes care group. To investigate the process of
diabetes care, the proportion of patients that received the
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guidelines for type 2 diabetes was calculated.
The cost diary at baseline and one year after baseline
was used to calculate health care use and costs over the
course of one year, using linear interpolation between
the two time measurements.
The proportion of patients visiting each health care pro-
vider (Chi2 tests) and mean number of visits per patient
for that specific health care provider (Mann-Whitney test)
were calculated. Despite the skewed distribution of health
care use and costs in our population, mean number of
visits and mean costs were reported because this is the
most informative measure from an economic perspective.
We differentiated between direct health care costs,
direct non-health care costs and indirect costs. Direct
health care costs consisted of costs related to visits to
health care providers, laboratory tests, use of home care
and hospitalizations. Direct non-health care costs in-
cluded the cost of visits to health care providers not paid
by patients’ health insurance. Indirect costs were costs
related to loss of productivity (paid and unpaid work).
Regression analysis was performed with direct health
care and non-health care costs, indirect costs, total direct
and total costs as dependent variables and type of care as
the independent variables, estimating differences in costs
between managed and usual care and between protoco-
lized and usual care. Multivariate regression models were
used to estimate differences in costs adjusted for con-
founding factors. Because of the skewed distribution of
the costs, bootstrapping methods (5000 replications) with
a bias-corrected and accelerated approach were used to
estimate 95% confidence intervals (CI) around the differ-
ences in costs [25].
In a sensitivity analysis, differences in costs were ana-
lyzed using linear multilevel regression analyses to ac-
count for clustering at the general practice level [26].
95% CI’s around cost differences were estimated using
bias-corrected bootstrapping with 5000 replications,
stratified for general practice to account for the cluster-
ing of data. Multilevel analysis was not possible for the
managed care group, due to the low number of patients
within each general practice included in our study.
Results
The mean age of diabetes patients was 65 years. Com-
pared to patients under usual care, a lower proportion of
patients receiving managed care were highly educated
(7.6 vs. 18.6%) and a lower proportion of patients receiv-
ing protocolized care was less educated (48.2 vs. 59.5%).
The use of glucose lowering medication was highest in
patients receiving managed care (88.2%) compared to
patients receiving protocolized (76%) care or usual care
(79.9%) Patients receiving protocolized care (5.6%) or
usual care (13.3%) were more likely to consult a specialistin internal medicine for diabetes care as compared to pa-
tients receiving managed care (1.0%, Table 1).
A significantly higher proportion of patients receiving
managed care reported that they received information
about self-control of feet, screening of the feet and meas-
urement of weight compared to protocolized and usual
care patients. Compared to usual care, more patients in
the managed care group were screened for retinopathy
and a higher proportion of patients in the protocolized
care group reported screening for nephropathy (Figure 1).
Patients receiving protocolized care had more consul-
tations with the diabetes nurse than patients receiving
managed care or usual care. Patients in the managed
care group visited the dietician more frequently than pa-
tients in the protocolized or usual care groups. Fewer
patients in the managed care group visited specialists in
internal medicine and ophthalmology and the mean num-
ber of these consultations was lower in this group than in
the protocolized and usual care groups (Table 2).
Direct and total direct health care costs were signifi-
cantly lower in the managed and protocolized care groups
compared to the usual care group. After adjustment for
confounding factors, differences in direct costs decreased,
but direct costs remained statistically significantly lower in
managed care than in usual care. Costs associated with
productivity loss (indirect costs) were comparable in the
protocolized and usual care groups, but was higher in pa-
tients receiving managed care as compared to protoco-
lized and usual care, although this relationship was not
statistically significant. Differences in indirect costs in-
creased after adjustment for diabetes duration, marital sta-
tus, educational level and retirement. Total costs were
lower in managed care and protocolized care compared to
usual care, although this relationship was not statistically
significant (Table 3).
Adjustment for clustering at the general practice levels
did not change the difference in costs between protoco-
lized and usual care and slightly increased the statistical
uncertainty (direct health care costs: -1057 (95% CI: -2114
to -166); total costs: -1228 (95% CI: -2443 to 67).
Discussion
Overall, managed care was associated with a better process
of diabetes care, higher use of primary health care, fewer
secondary care consultations and lower health care costs
compared to usual care. The same trends were seen for
protocolized care, however differences in costs were not
statistically significant after adjustment for differences in
patient characteristics between the care groups.
The results of our study are in line with previous stud-
ies showing that an increased focus on the adherence of
guidelines leads to an improved process of the diabetes
care [27]. More specifically, patients receiving structured
or specialized diabetes care were more frequently treated











care(n = 215) (n = 197) (n = 333)
Men (%) 52.1 53.8 51.1 0.81 0.54
Age (years) 64.6 (7.4) 65.5 (7.5) 64.4 (7.0) 0.66 0.07
Diabetes duration (years) 6 (2-11) 5 (3-10) 6 (3-10) 0.85 0.74
Married/living together (%) 81.1 78.2 80.4 0.84 0.54
Educational level (%) <0.01 0.04
- low 52.8 48.2 59.5
- medium 39.6 28.4 21.9
- high 7.6 23.4 18.6
Paid job (%) 17.9 26.4 18.6 0.84 0.04
Retired (%) 47.2 45.7 44.4 0.53 0.78
Disabled (%) 9.4 3.6 6.0 0.14 0.22
Smoking status (%) 0.48 0.25
- current 16.8 12.3 16.2
- former 55.1 55.2 52.0
- never 28.1 32.5 31.8
Treatment (%) 0.05 <0.01
- diet only 11.8 24.0 20.1
- oral medication 67.3 64.1 56.8
- insulin 8.1 1.6 10.0
- insulin and oral medication 12.8 10.4 13.1
Treated in secondary care (specialist in internal medicine) 1.0 5.6 13.3 <0.01 0.01























































Figure 1 Proportion of patients reporting that they received a
specific medical examination during the last year. *Indicates a
significant difference (P < 0.05) between managed and usual
diabetes care. †Indicates a significant difference between
protocolized and usual care. §Indicates a significant difference
between managed and protocolized care.
van der Heijden et al. BMC Health Services Research 2014, 14:280 Page 5 of 8
http://www.biomedcentral.com/1472-6963/14/280according to the guidelines for type 2 diabetes [14,28,29].
The lower costs associated with managed care compared
to usual care is comparable with recent studies showing
that an increasing level of structured care was associated
with decreased costs [15,30]. In these studies, information
on costs was obtained by claims paid for covered health
care use. Detailed information on health care use or costs
from a societal perspective was unavailable. To obtain
information on health care use to calculate costs of care,
self-administered three-month cost diaries were used.
Self-reporting of information might have led to an under-
reporting of health care use due to recall bias [31]. How-
ever, because of the prospective design of the cost diary,
recall bias and underreporting of data is unlikely. Previous
research comparing data obtained by cost diaries with data
retrieved from insurance companies showed that cost
diaries are a feasible and valid tool with which to measure
costs [23]. Furthermore, the use of the cost diary at base-
line and at one year after baseline to calculate health care
use and costs leads to more reliable estimates than a single
measurement. Using this method, we were also able to ob-
tain indirect costs and costs not covered by health insur-
ance companies. Patients who did not complete two cost
Table 2 Resource use and productivity loss stratified by diabetes care over one year
Managed care Protocolized care‡ Usual care‡
N = 215 N = 197 N =333
Consultation of .. % ≥1 visits Mean (SD) # of visits % ≥1 visits Mean (SD) # of visits % ≥1 visits Mean (SD) # of visits
General practitioner 77.8 7.6 (8.6) 80.0 5.7 (6.9) 78.4 6.1 (6.9)
Diabetes nurse 74.5ab 3.8 (3.8)b 82.6 4.3 (3.5)a 84.5 3.7 (2.8)
Dietician 38.4ab 1.4 (2.4)ab 20.5 0.9 (2.2) 21.9 0.9 (2.4)
Podiatrist 19.4b 0.7 (1.8)b 9.2a 0.4 (1.6)a 24.3 1.2 (2.9)
Physical therapist 25.9 5.3 (13.8) 30.3a 7.3 (18.1)a 21.0 3.9 (11.9)
Specialist in
- Internal medicine 6.9ab 0.4 (2.0)ab 15.4a 0.6 (1.7)a 28.9 1.5 (2.8)
- Ophthalmology 17.6ab 0.8 (2.5)ab 47.7 1.5 (2.5) 52.0 1.8 (2.6)
- Cardiology 15.7 0.6 (2.5) 15.4 0.7 (1.9) 15.2 0.7 (2.3)
- Neurology 5.1 0.2 (0.9) 6.2 1.6 (0.7) 6.4 0.6 (4.0)
- Nephrology 1.4 0.0 (0.4) 3.6 0.2 (1.3) 1.8 0.1 (0.4)
Other specialism 25.9 1.4 (3.1) 27.7 1.4 (2.9) 32.8 1.6 (4.0)
Hospitalization 9.7 0.7 (3.0) 10.3 1.1 (4.7) 12.5 2.7 (14.8)
Absenteeism paid work 8.8 4.9 (27.8) 10.8 2.8 (14.1) 10.0 3.1 (15.2)
Absenteeism unpaid work 13.9 12.3 (50.0) 9.7 18.2 (127.4)a 18.2 20.7 (70.6)
Data are expressed as proportions of patients who used the specific resource and mean (SD) resource use per patient over one year. aSignificantly different
(P < 0.05) from usual care. bSignificantly different (P < 0.05) from protocolized care.
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sulted in the selection of healthier diabetes patients. How-
ever, with the exception of age and marital status, patient
characteristics did not differ statistically significantly be-
tween those included in and excluded from the study.
In the managed care group, many of the patients were
disabled and more patients reported sick leave compared
to patients in the protocolized and usual care groups. It
has been shown that individuals with less education are at
increased risk for sick leave [32], which may provide an





Usual care Mean diffe
managed
(n = 215) (n = 197) (n = 333) Model 1
Direct health
care costs





17 (102) 19 (127) 13 (92) 4 (-10 to 2
Total direct
costs




1727 (8808) 1125 (4548) 1328 (4840) 461 (-524 to
Total costs 3003 (9457) 2711 (5690) 3949 (10328) -882 (-2415 to
Usual care is the reference category.
Model 1: adjusted for age and sex.
Model 2: further adjusted for diabetes duration, marital status, educational level and
aSignificantly different (P < 0.05) from usual care.in which only 7.6% of the patients were highly educated.
Managed and protocolized care was implemented at the
general practice level and organized regionally. Random
allocation of patients to the intervention or control group
was therefore not feasible. Despite adjustment for differ-
ences in patient characteristics between the care groups,
uncontrolled biases might have affected the results. Of the
characteristics that differed between patients of the three
groups, age, educational level and work status significantly
affected the results. Differences between groups in treat-
ment did not influence the results.ces in costs (€) between groups
rences in costs between
and usual care (95% CI)
Mean differences in costs between
protocolized and usual care (95% CI)






-794 (-2082 to 52)






-788 (-2042 to 47)
2277) 758 (-353 to 2701) -78 (-782 to 836) -96 (-844 to 823)
932) -423 (-2146 to 1566) -1128 (-2682 to 86) -884 (-2281 to 323)
retirement.
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care were implemented in a well functioning Dutch pri-
mary care system which may have resulted in smaller
differences between patients receiving managed or pro-
tocolized care and patients treated in accordance with
usual care. However, we do believe that the results of
our study can be extrapolated to other countries and
other health care systems with high referral rates to sec-
ondary care [33].
Our results indicate that a part of health care use can
be substituted by the implementation of managed care
in particular, resulting in fewer consultations with spe-
cialists at the secondary care level. This substitution of
secondary care for primary care was not associated with
a lower quality of care compared to usual care. Instead,
managed care performed better in terms of the process
of care. More patients in the managed care group re-
ceived assessments and screenings according to diabetes
guidelines, which might have resulted in the detection of
complications at an early stage and early initiation of
appropriate treatment, which may, consequently, reduce
the number of complications in the long run.
Conclusions
The implementation of managed diabetes care, with a
high level of centralization, embedded in primary care re-
sulted not only in a better process of diabetes care, but
also in lower health care costs. The combination of better
process of care and reduced costs is of great importance
particularly for a highly prevalent, chronic disease such as
type 2 diabetes, which makes this form of managed care a
promising strategy for treating the growing population of
type 2 diabetes patients.
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